Real-world effectiveness of Anti-CGRP monoclonal antibodies compared to OnabotulinumtoxinA (RAMO) in chronic migraine: a retrospective, observational, multicenter, cohort study

Table 2 Efficacy outcomes

	Anti-CGRP mAbs	BoNT-A	Unadjusted Mean difference (95%CI)	p-value	Adjusted Mean difference (95%CI)	p-value	Propensity score matched Mean difference (95%CI)	p-value
Primary outcome
MHD 12 months change from baseline, mean (SD)	-11.9 (6.1)	-7.6 (8.5)	-4.4 (-6.8 to -2.0)	0.0002	-6.2 (-9.2 to -4.7)	< 0.001	-7.6 (-10.9 to -4.3)	< 0.001
	n = 69	n = 85
Secondary outcomes
MHD 6 months change from baseline, mean (SD)	-11.5 (6.3)	-7.2 (8.7)	-4.3 (-6.6 to -2.0)	0.0003	-7.1 (-9.5 to -4.7)	< 0.001	-6.7 (-11.2 to -2.2)	0.004
	n = 80	n = 91
MIDAS 12 months change from baseline, mean (SD)	-62.3 (43.8)	-43.1 (59.8)	-19.2 (-36.4 to -1.9)	0.0296	-18.5 (-37.7 to 0.7)	0.059	-7.3 (-41.6 to 27.1)	0.678
	n = 69	n = 79
MIDAS 6 months change from baseline, mean (SD)	-67.3 (41.1)	-35.7 (60.2)	-31.7 (-47.4 to -15.9)	0.0001	-34.3 (-52.7 to -16.0)	< 0.001	-30.0 (-51.5 to -8.4)	0.006
	n = 80	n = 91
MAM 12 months change from baseline, mean (SD)	-11.4 (9.1)	-8.2 (10.8)	-3.1 (-6.4 to 0.1)	0.0574	-5.6 (-9.3 to -2.0)	0.003	-8.1 (-11.8 to -4.3)	< 0.001
	n = 69	n = 85
MAM 6 months change from baseline, mean (SD)	-11.7 (9.2)	-6.6 (11.8)	-5.1 (-8.3 to -1.8)	0.0023	-7.6 (-11.4 to -3.9)	< 0.001	-7.4 (-10.5 to -4.5)	< 0.001
	n = 80	n = 91

The number of patients included in each analysis is reported under the corresponding results
Abbreviations: 95%CI 95% confidence interval, BoNT-A Onabotulinumtoxin-A, CGRP Calcitonin gene related peptide, mAbs Monoclonal antibodies, MAM Migraine acute medications, MHD Monthly headache days, MIDAS Migraine disability assessment test, SD Standard deviation

ISSN: 1129-2377